Latest News

To report the outcomes of stereotactic ablative body radiotherapy (SABR) in men with oligometastatic prostate cancer (PCa) diagnosed on prostate-specific membrane antigen (PSMA)-positron emission tomography/computed tomography (PET/CT), based on a single-institution experience and the published literature. This was a retrospective cohort study of the first 20 consecutive men with oligometastatic PCa, treated with SABR in […]

Radiolabelled small molecules for imaging prostate cancer have rapidly emerged over the last few years with gallium-68-labelled prostate-specific-membrane-antigen-11 (68Ga-PSMA11), the most widely used. However, the current evidence-based guidelines for management of prostate cancer were established using computed tomography (CT), magnetic resonance imaging (MRI) and bone scan, despite their limitations. Prostate-specific-membrane antigen (PSMA) positron-emission tomography (PET)/CT, […]

This study aims to assess the diagnostic role of F-FDG PET/computed tomography in primary staging and restaging of testicular cancer in comparison with contrast-enhanced diagnostic thoracic-abdominopelvic computed tomography. Thirty-two consecutive male patients with testicular carcinoma (median age: 29, min-max: 17-65) who were referred to the nuclear medicine department for F-FDG PET/computed tomography were retrospectively included […]

A role for local therapies including radical prostatectomy (RP) in prostate cancer (PCa) patients with clinical lymphadenopathies has been proposed. However, no data are available to identify men who would benefit from RP in this setting. To identify predictors of clinical recurrence (CR) in surgically managed PCa patients with clinical lymphadenopathies. We identified 162 patients […]

Barcelona, Spain (UroToday.com) Thomas Powles, MBBS, discussed the results presented in a prior ESMO 2019 session of the IMVigor130 study of atezolizumab as monotherapy or in combination with platinum chemotherapy compared with chemotherapy alone as first line therapy in locally advanced or metastatic urothelial carcinoma. Immunotherapy with either pembrolizumab or atezolizumab has been recently improved […]

Barcelona, Spain (UroToday.com) Interim results from APACHE have been published, with the monotherapy (durvalumab) arm stopped for futility among patients with refractory germ cell tumors1. The evidence from the durvalumab monotherapy arm were even more negative than that reported for monotherapy pembrolizumab amongst similar patients2. At the European Society of Medical Oncology (ESMO) 2019 Annual […]